ADCT Q1 2026 Earnings Call Summary

ADC Therapeutics Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Net Product Revenues: $20.0 million for Q1 2026, up from $17.4 million in Q1 2025, reflecting a 15% year-over-year growth.
Licensing Revenues: Decreased due to a $5 million milestone payment received in the prior year.
Cost of Product Sales: Increased by $1.6 million to $3.6 million, attributed to a shift in personnel costs from R&D to commercial manufacturing.
Total Operating Expenses: $46.1 million; on a non-GAAP basis, adjusted operating expenses were $42.9 million, down 13% from the previous year.
Net Loss: GAAP net loss of $33 million ($0.21 per share), improved from a loss of $38.6 million ($0.36 per share) in Q1 2025. Non-GAAP adjusted net loss was $19.7 million, compared to $24 million in the prior year.
Cash Position: Ended Q1 2026 with $231 million in cash, providing a runway into 2028.

2. Strategic Updates and Business Highlights

ZYNLONTA: The company is focused on maintaining ZYNLONTA as a key treatment for third-line plus DLBCL patients, with plans to expand its use into earlier lines of therapy.
LOTIS-5 Trial: Top-line data expected by the end of June 2026, which could lead to a supplemental biologics license application (sBLA) submission by year-end.
LOTIS-7 Trial: Enrollment of approximately 100 patients expected to be completed in Q2 2026, with full data anticipated by year-end.
Indolent Lymphomas: Data publication from ongoing trials expected between late 2026 and mid-2027.

3. Forward Guidance and Outlook

Anticipated revenue growth trajectory beginning in 2027, contingent on positive LOTIS-5 results and subsequent approvals.
Potential peak annual revenues for ZYNLONTA projected at $600 million to $1 billion in the U.S. if regulatory approvals and compendia listings are achieved.
Continued focus on cost management and capital discipline to support growth initiatives.

4. Bad News, Challenges, or Points of Concern

Competitive Pressures: Despite stable demand, the company acknowledges a competitive environment that may impact market share.
Revenue Variability: The increase in revenues is partly attributed to quarter-to-quarter variability in customer ordering, making it difficult to ascertain a definitive growth trend.
Operating Losses: The company continues to report significant net losses, although improvements have been made year-over-year.

5. Notable Q&A Insights

Data Blinding: The management confirmed that they remain blinded to LOTIS-5 data, with no specific timeline provided for when the database will be locked.
Sales Growth Drivers: Management indicated that while Q1 showed stronger sales, it is too early to declare a consistent upward trend due to historical variability.
LOTIS-5 Data Disclosure: The company plans to disclose comprehensive information on primary and secondary endpoints, including median progression-free survival (PFS) and overall survival (OS) trends, during the top-line announcement.
Cost of Goods: The shift in personnel costs to cost of goods is expected to continue, leading to increased costs in future quarters.

Overall, ADC Therapeutics is positioned for potential growth with ZYNLONTA, but faces challenges related to competitive pressures and ongoing operating losses. The upcoming LOTIS-5 trial results are critical for the company's future trajectory.

ADCT — ADC Therapeutics S.A.